ID   A375 RL
AC   CVCL_E8FX
SY   A375-RL
DR   ABM; T3350
RX   PubMed=31877948;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Leg, skin; UBERON=UBERON_0001511.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0132 ! A-375
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=31877948; DOI=10.3390/ijms21010113; PMCID=PMC6981576;
RA   Dratkiewicz, Ewelina
RA   Simiczyjew, Aleksandra
RA   Pietraszek-Gremplewicz, Katarzyna
RA   Wadzynska, Justyna
RA   Nowak, Dorota
RT   "Characterization of melanoma cell lines resistant to vemurafenib and
RT   evaluation of their responsiveness to EGFR- and MET-inhibitor
RT   treatment.";
RL   Int. J. Mol. Sci. 21:113.1-113.20(2019).
//